Cargando…
Early stage and long term treatment of multiple sclerosis with interferon-β
Multiple sclerosis (MS) affects young adults during the most productive years of their lives, and until recently many neurologists were limited to treating symptoms and attacks without any ability to alter the disease course. The 1990s ushered in an era of possibility with the approval of three inte...
Autores principales: | Applebee, Angela, Panitch, Hillel |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726076/ https://www.ncbi.nlm.nih.gov/pubmed/19707414 |
Ejemplares similares
-
Bone marrow sarcoidosis associated with long‐term interferon‐β treatment for multiple sclerosis
por: Teh, Angela, et al.
Publicado: (2016) -
Long-Term Consequences of High Titer Neutralizing Antibodies to Interferon-β in Multiple Sclerosis
por: Dunn, Nicky, et al.
Publicado: (2020) -
Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta
por: Castrop, Florian, et al.
Publicado: (2013) -
Thrombotic Microangiopathy Presenting with Intestinal Involvement Following Long-term Interferon-β1b Treatment for Multiple Sclerosis
por: Omoto, Shusaku, et al.
Publicado: (2017) -
Clinical testing for neutralizing antibodies to interferon-β in multiple sclerosis
por: Creeke, Paul I., et al.
Publicado: (2013)